All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The FDA's approval of GW Pharma plc's liquid Epidiolex – the first pharmaceutical formulation of purified, plant-based cannabidiol (CBD) to reach the market – in Dravet syndrome (DS) and Lennox-Gastaut syndromes (LGS) opens the door to a new therapeutic and regulatory world.